Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Howard Grattan

Pain Medicine Gresham, OR Medical Doctor

NPI 1902973266 CMS profile 359323

689 Nw Burnside Rd, Gresham, OR 97030

Open in the dashboard

General payments

$4,557

162 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Howard Grattan of Gresham, OR is reported in the CMS Open Payments database as having received $4,557 across 162 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,630 24
2024 General $353 11
2023 General $226 7
2022 General $342 17
2021 General $601 30
2020 General $466 27
2019 General $938 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Grattan
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Howard Grattan were reported at $1,630. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Howard Grattan Pain Medicine median Middle half National median
2019 $938 $409 $115–$1,311 $163
2020 $466 $214 $66–$666 $114
2021 $601 $299 $84–$899 $132
2022 $342 $335 $103–$1,149 $149
2023 $226 $376 $114–$1,228 $160
2024 $353 $387 $115–$1,173 $164
2025 $1,630 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $2,022 29 payments
  2. AbbVie, Inc. $429 21 payments
  3. Nevro Corp. $286 7 payments
  4. Allergan Inc. $267 17 payments
  5. Pfizer Inc. $185 15 payments
  6. Collegium Pharmaceutical, Inc. $185 10 payments
  7. Amgen Inc. $123 7 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $119 6 payments
  9. Novartis Pharmaceuticals Corporation $88 6 payments
  10. Lilly USA, LLC $87 5 payments
  11. Other $766 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,520 157 payments
  2. Travel and Lodging $1,036 5 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Structural Heart $1,092 6 payments
  2. UBRELVY $311 15 payments
  3. BOTOX $254 16 payments
  4. Senza Spinal Cord Stimulation System $253 5 payments
  5. AIMOVIG $212 13 payments
  6. PROCLAIM Neuromodulation $206 5 payments
  7. ETERNA $169 4 payments
  8. LYRICA $145 13 payments
  9. AXIUM $139 1 payment
  10. Proclaim Family of SCS IPGs $137 3 payments
  11. Other $1,921 106 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$40,107

Of which drugs: $642

Medicare patients

83

Average age 71

Services billed

2,788

55 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Depression 52%
Chronic kidney disease 31%
Diabetes 27%
Heart failure 18%
Ischemic heart disease 18%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 41 2,200 $596
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 34 341 $27
Injection, midazolam hydrochloride, per 1 mg J2250 Office 22 23 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $43
$43 — —
BELBUCA
  • Collegium Pharmaceutical, Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record